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In addition to genetic predisposition, environmental and
lifestyle factors contribute to the pathogenesis of type 2
diabetes (T2D). Epigenetic changes may provide the link
for translating environmental exposures into pathological
mechanisms. In this study, we performed the ﬁrst com-
prehensive DNA methylation proﬁling in pancreatic islets
from T2D and non-diabetic donors. We uncovered 276 CpG
loci afﬁliated to promoters of 254 genes displaying signiﬁ-
cant differential DNA methylation in diabetic islets. These
methylation changes were not present in blood cells from
T2D individuals nor were they experimentally induced in
non-diabetic islets by exposure to high glucose. For a
subgroup of the differentially methylated genes, concor-
dant transcriptional changes were present. Functional
annotation of the aberrantly methylated genes and RNAi
experiments highlighted pathways implicated in b-cell
survival and function; some are implicated in cellular
dysfunction while others facilitate adaptation to stressors.
Together, our ﬁndings offer new insights into the intricate
mechanisms of T2D pathogenesis, underscore the important
involvement of epigenetic dysregulation in diabetic islets
and may advance our understanding of T2D aetiology.
The EMBO Journal (2012) 31, 1405–1426. doi:10.1038/
emboj.2011.503; Published online 31 January 2012
Subject Categories: chromatin & transcription; molecular
biology of disease; genomic & computational biology
Keywords: DNA methylation; pancreatic islets; type 2
diabetes
Introduction
Type 2 diabetes (T2D) has developed into a major public
health concern. While previously considered as a problem
primarily for western populations, the disease is rapidly
gaining global importance, as today around 285 million
people are affected worldwide (IDF, 2009). Lifestyle and
behavioural factors play an important role in determining
T2D risk. For example, experimentally induced intrauterine
growth retardation as well as nutrient restriction during
pregnancy in rats have been shown to result in development
of T2D in offspring (Inoue et al, 2009) while chronic high-fat
diet in fathers programs b-cell dysfunction in female rat
offspring (Ng et al, 2010). In humans, a reduced birth weight
together with an accelerated growth in infancy has been
associated with impaired glucose tolerance (IGT) in adult-
hood (Bhargava et al, 2004). The pancreatic islets of
Langerhans are of central importance in the development of
T2D. Under normal conditions, increasing blood glucose
levels after a meal trigger insulin secretion from the pancrea-
tic islet b-cells to regulate glucose homeostasis. b-Cell failure
marks the irreversible deterioration of glucose tolerance
(Cnop et al, 2007b; Tabak et al, 2009) and results in T2D
(UKPDSG, 1995). The unbiased genome-wide search for T2D
risk genes (Saxena et al, 2007; Scott et al, 2007; Sladek et al,
2007; Zeggini et al, 2007, 2008) has placed the insulin-
producing b-cells at centre stage. These approaches have
also inadvertently highlighted the complexity of the biologi-
cal mechanisms critical to T2D development. Most T2D risk
genes identiﬁed in these genome-wide association studies
(GWAS) affect b-cell mass and/or function (Florez, 2008).
While the majority of studies in the ﬁeld have characterised
diabetes aetiology on the basis of genetics, new ﬁndings
suggest the potential involvement of epigenetic mechanisms
in T2D as a crucial interface between the effects of genetic
predisposition and environmental inﬂuences (Villeneuve and
Natarajan, 2010). Epigenetic changes are heritable yet rever-
sible modiﬁcations that occur without alterations in the
primary DNA sequence. DNA methylation and histone
modiﬁcations are the main molecular events that initiate
and sustain epigenetic modiﬁcations. These modiﬁcations
may therefore provide a link between the environment, that
is, nutrition and lifestyle, and T2D but only few studies so far
have documented aberrant DNA methylation events in T2D
(Ling et al, 2008; Park et al, 2008).
DNA methylation occurs as 5-methyl cytosine mostly in
the context of CpG dinucleotides, so-called CpG sites. It is the
best-studied epigenetic modiﬁcation and governs transcrip-
tional regulation and silencing (for review, see Suzuki and
Bird, 2008). Unlike the relatively study genome, the methy-
lome changes in a dynamic way during development, tissue
differentiation and aging. Pathologically altered DNA methy-
lation is well described in various cancers (reviewed in Jones
and Baylin, 2007) and its role is starting to be revealed
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1405in several other diseases such as multiple sclerosis (Casaccia-
Bonneﬁl et al, 2008), Alzheimer’s disease (Mastroeni et al,
2009) and systemic lupus erythematosus (Javierre et al,
2010). About 75% of human gene promoters are associated
with CpG islands (CGIs) (Jones and Baylin, 2007; Suzuki and
Bird, 2008), which are clusters of 500bp to 2kb length with a
comparatively high frequency of CpG dinucleotides. They
usually harbour low levels of DNA methylation but can
become hypermethylated; this CGI hypermethylation was
demonstrated to abrogate transcription of tumour suppressor
genes during tumourigenesis (Jones and Baylin, 2007).
Lately, DNA methylation changes in CpG sites adjoining yet
outside of CGIs, so-called CGI shores (Irizarry et al, 2009), are
gaining increased attention. Intriguingly, CpG sites in these
shore sequences, in addition to those within CGIs, are
proposed to display differential DNA methylation between
cancer and normal cells as well as between cells of different
tissues (Irizarry et al, 2009).
The goal of the present work was to clarify the hitherto
poorly understood connection between DNA methylation and
T2D pathogenesis and to determine whether identiﬁed
epigenetic changes translate into functional effects that
impinge on pancreatic b-cell function. For this, we have
explored DNA methylation landscapes in islets isolated
from T2D patients and non-diabetic individuals.
Results
Identiﬁcation of the T2D-related differential DNA
methylation proﬁle
We performed DNA methylation proﬁling to analyse the
methylomes of freshly isolated islets from 16 human cada-
veric donors of similar age, BMI and ethnicity (5 diabetic and
11 non-diabetic Caucasian donors; Table I). Using electron
microscopy (EM), we examined the purity of the islet pre-
parations (see Supplementary data). In diabetic islets,
decreases in the percentage of b-cells have been reported
(Sakuraba et al, 2002; Rahier et al, 2008). As shifts in the
composition of islet cell types (especially b-cells that consti-
tute about two thirds of the islet cell mass) with different
epigenomes might overlay T2D-related changes in the cells’
DNA methylation patterns, we used EM to estimate the
percentage of b-cells. The amount of b-cells in three ran-
domly chosen control islet preparations was 66.3±0.9%.
Diabetic islets (n¼3, randomly chosen) contained only
marginally less b-cells, accounting for 59.7±1.7% of total
islet cell number (cf. Supplementary Table S1, Materials and
methods, Supplementary data).
To perform DNA methylation proﬁling, we used the
recently developed Inﬁnium Methylation Assay (Illumina
s
Inﬁnium
s HumanMethylation27 BeadChip; Supplementary
Figure S1; Bibikova et al, 2009). This assay interrogates the
methylation status of 27578 CpG sites corresponding to
14475 consensus coding sequences and well-known cancer
genes (Bibikova et al, 2009). Although the Inﬁnium methyla-
tion assay is not a genome-wide DNA methylation technol-
ogy, it is a useful screening tool that is sensitive, speciﬁc and
highly reproducible (Bibikova et al, 2009) allowing for ana-
lysis of a deﬁned set of CpG sites in a large number of
samples. The analysed CpGs are primarily located in prox-
imal promoter regions (and preferentially inside CGIs) and
the array encompasses probes with an average coverage of
1.9 CpG sites per promoter.
As an initial step, we evaluated whether DNA methylation
changes in T2D were sufﬁcient to distinguish the diabetic
from the control samples when comparing complete methy-
lation proﬁles. For this, an unsupervised hierarchical cluster-
ing was performed which placed the diabetic islet samples as
one self-contained group distinct from the control samples in
the resulting dendrogram (Supplementary Figure S2). This
outcome highlights two facts: ﬁrst, diabetic DNA methylation
proﬁles are more similar to each other than to the methyla-
tion proﬁle of any control sample, indicating the possibility of
a T2D-speciﬁc DNA methylation proﬁle; second, the exis-
tence of a single branch containing the ﬁve diabetic samples
shows that the DNA methylation changes are sufﬁciently
pronounced (even in the unﬁltered data sets) to distinguish
diabetic from control samples. To further substantiate the
correlation of variations of DNA methylation with T2D, we
performed a principal component analysis on the data set
(Materials and methods; Supplementary Figure S3) and com-
pared the resulting principal components with the T2D state
in a point-biserial correlation (Lowry, 1998–2011). We found
that PC #1 and PC #3, together accounting for 37% of the
variance in the data set, correlate well with T2D state
(Supplementary Figure S3). This is indicative of distinct,
T2D-speciﬁc changes in the epigenome of pancreatic islets.
Following this initial data analysis, we identiﬁed T2D-
related methylation changes by ﬁltering the data sets for
CpG sites showing signiﬁcant differences in DNA methylation
levels between control and T2D groups (cf. Materials and
methods and Supplementary Table S2). The results of the
ﬁltering are shown as a heatmap (Figure 1A). The depicted
methylation proﬁles discriminate between control samples
(left side, indicated by yellow bar above heatmap) and T2D
samples (right side, indicated by blue bar). It is already
apparent from the above data that there are marked DNA
methylation changes in T2D islets. The number of differen-
tially methylated CpG loci in T2D islets is in the same range
as reported for other non-malignant conditions analysed with
the same technology platform (19 in T1D-related nephropa-
thy; Bell et al, 2010); 84 and 360, respectively, in analyses
of ageing in cells and tissue specimens (Bork et al, 2009;
Rakyan et al, 2010).
We then set out to evaluate the descriptive power of the
CpG sites in the ﬁltered data set to differentiate diabetic from
non-diabetic specimens in sample-wise comparisons. We
therefore extracted the methylation values for each sample
and performed a supervised clustering (Figure 1B, cf.
Materials and methods). As expected, the resulting dendro-
gram shows that samples group together in two clusters
containing exclusively control (CTL, yellow bar) or diabetic
(T2D, blue bar) samples, indicating that class identity (CTL,
T2D) is the most important separation criterion (Figure 1B,
Table I Pancreatic islet donor characteristics
CTL T2D
Number of samples 11 5
Age (years) 57.2±15.2 64.4±5.3 (P¼0.33)
BMI (kg/m
2) 27.0±1.1 26.5±2.2 (P¼0.8)
Glucose-induced insulin secretion (ratio of secretion at
16.7mM/3.3mM glucose)
3.59±1.05 1.24±0.3 (Po0.001)
DNA methylation proﬁling of type 2 diabetic islets
M Volkmar et al
The EMBO Journal VOL 31 | NO 6 | 2012 &2012 European Molecular Biology Organization 1406left-most branch). To assess clustering conﬁdence in an
unbiased way and to overcome inherently subjective visual
interpretation of the results depicted in the heatmap
(Figure 1A), a bootstrapping analysis was carried out after
dendrogram computation (cf. Materials and methods). The
obtained bootstrap of 0.85 indicates signiﬁcant statistical
support for the bipartite distribution between diabetic and
non-diabetic samples based on the analysis of the CpGs
contained in the ﬁltered data set. The occasional high boot-
strap values adjoined to sample pairs illustrate similarities in
the DNA methylation proﬁles of these samples. These data
demonstrate that human pancreatic islets undergo DNA
methylation alterations in T2D that are discernible by
means of DNA methylation proﬁles.
T2D-related aberrations encompass mostly
promoter-speciﬁc DNA hypomethylation
The above experiments enabled us to collect the ﬁrst com-
prehensive DNA methylation data set for T2D human islets.
We identiﬁed 276 CpG sites, afﬁliated to 254 gene promoters,
showing differential methylation between normal and dis-
eased samples (Figure 1C; Supplementary Table S2).
Strikingly, 266 of these 276 CpGs (96%) showed decreased
methylation levels, while only 10 were hypermethylated
(Figure 1C). This unexpected ﬁnding contrasts with the
well-known DNA methylation changes observed in cancers,
where gene-speciﬁc hypomethylation and hypermethylation
are more or less evenly distributed (Jones and Baylin, 2007).
With respect to global DNA methylation, cancers generally
display hypomethylation (Jones and Baylin, 2007; Tost,
2010), primarily in repetitive DNA.
To test whether the observed T2D-related changes are gene
speciﬁc or whether they reﬂect global hypomethylation in the
genome of islet cells, we measured DNA methylation levels of
the repetitive LINE-1 element in control and diabetic samples
with bisulphite pyrosequencing (BPS). Analysing DNA
methylation of LINE-1, which makes up B20% of human
genome, provides an accurate estimate of global DNA
Figure 1 Hierarchical proﬁle-based clustering and evaluation of T2D islet DNA methylation. (A) A heatmap of the differentially methylated
CpG loci shows distinct patterns separating data sets obtained from CTL (yellow line above heatmap) and T2D samples (blue line).
(B) Supervised clustering based on the differentially methylated CpG loci separates T2D from control samples. As an indication of statistical
signiﬁcance, bootstrap values (40.7) are shown next to the branches. Note that the order of samples in the heatmap in Figure 1A follows the
one established by supervised clustering. (C) Pie chart depicting the 276 CpG sites showing differential methylation between T2D and control
samples (see also Supplementary Table S2). Note the high proportion of hypomethylation events as compared with hypermethylation events.
(D) LINE-1 repetitive element DNA methylation for CTL and T2D samples by BPS (n¼11 for CTL; n¼5 for T2D).
DNA methylation proﬁling of type 2 diabetic islets
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repetitive elements are not differentially methylated in T2D,
as substantiated by the strong overlap between CTL and T2D
samples, indicating the absence of global hypomethylation in
T2D islets.
As an additional quality control, we examined the set of
276 differentially methylated CpG sites for overlap with
known single-nucleotide polymorphism (SNP) positions to
be excluded from further data analysis. We found no overlap
with the reported 180 potentially problematic CpG sites
contained in the Humanmethylation27 array (Bell et al,
2011) and therefore continued our analyses with the full set
of 276 CpGs.
BS validation of T2D-related differential DNA
methylation
To corroborate the observed Inﬁnium measurements (cf.
Figure 1 and Supplementary Table S2), we applied BPS and
in some cases conventional BS to randomly selected, differ-
entially methylated CpG sites. In all 19 cases tested, differ-
ential DNA methylation at the respective CpG sites was
conﬁrmed by BPS (Figure 2; Supplementary Figure S4).
Where implemented, BS also conﬁrmed the DNA methylation
proﬁling data (Figure 2A; Supplementary Figure S4A).
Figure 2A depicts an exemplary analysed gene, ALDH3B1,
for which the Inﬁnium data were conﬁrmed by BS and BPS.
Additional validated genes are shown in Figure 2B (CASP10)
and Figure 2C (PPP2R4 alias PP2A). We discovered two
differentially methylated CpG sites inside a CGI in the IGF2/
IGF2AS locus. The differential methylation of one of the CpGs
in this region was tested and conﬁrmed by BPS (Figure 2D).
Further examples are shown in Supplementary Figure S4.
A direct comparison of methylation percentages obtained by
the Inﬁnium Methylation assay and BPS (Figure 2E) yielded a
highly positive correlation (Pearson’s correlation R¼0.927)
conﬁrming the validity of the data. BPS analysis of three
negative controls constituting high (490%), intermediate
(B40%) and low (o10%) levels of DNA methylation showed
expectedly no differential DNA methylation between sample
groups (Supplementary Figure S4M–O). Of note, CpG sites
neighbouring the Inﬁnium-assayed site are often encom-
passed in the BPS experiments (cf. Figure 2 and
Supplementary Figure S4); these adjacent CpG sites also
displayed similar DNA methylation levels. Hence, our valida-
tion experiments indicate that individual CpGs from the
Inﬁnium Methylation array can be used as informative
markers for the methylation status of the respective sur-
rounding regions. Taken together, BPS and BS results conﬁrm
the methylation values obtained from the Inﬁnium-based
assay, thus validating the T2D-speciﬁc DNA methylation
proﬁles.
Genomic features associated with differential DNA
methylation in T2D
Having shown that the observed differential DNA methyla-
tion in T2D is gene-speciﬁc rather than global (cf. Figure 1D),
we set out to determine whether this aberrant DNA methyla-
tion is (a) located within or outside CGIs, (b) prevalent in
distinct promoter classes (that are based on CpG density) or
(c) correlated with speciﬁc regulatory elements.
Previous work that investigated the localisation of differ-
ential DNA methylation in cancer and different tissues has
suggested that substantial DNA methylation differences occur
in CGI shores (Doi et al, 2009; Irizarry et al, 2009). We used
bioinformatic tools to determine the distance of differentially
methylated CpGs to the nearest CGI. Utilising CGI prediction
(Bock et al, 2007), we found that B50% of the differentially
methylated CpG sites are located 42kb from the nearest CGI
(‘other CpGs’ in Figure 3A and B and Supplementary Table
S3). Additionally, about one quarter of CpGs resides in CGI
shores (1–2000bp from a CGI border) while another quarter
of CpG sites was located inside CGIs (Figure 3A;
Supplementary Tables S2 and S3). A more detailed represen-
tation of the CpG distribution reveals the sites of differential
methylation inside the CGI shores to be located preferentially
close to the CGIs (bar chart in Figure 3B). This distribution of
differentially methylated sites inside CGI shores is similar to
regions showing differential methylation in cancer (c-DMRs;
Irizarry et al, 2009), between tissues (t-DMRs; Irizarry et al,
2009) and during differentiation/cell reprogramming (r-
DMRs; Doi et al, 2009). However, an overall comparison of
differential methylation locations between these DMRs (Doi
et al, 2009; Irizarry et al, 2009) and our data (Figure 3A and
B) shows signiﬁcant disparity, with a predominance of DNA
methylation changes 42kb away from CGIs (‘other CpGs’ in
Figure 3A and B and Supplementary Table S3), thus distin-
guishing the localisation of the DNA methylation proﬁle in
T2D islets from those found in tumours, between tissues and
in stem cells.
We next analysed the occurrence of these differentially
methylated CpG sites in relation to CpG density of the
afﬁliated gene promoters. Saxonov et al (2006) discovered a
bipartite distribution of gene promoters with minor overlap
between both classes when categorising promoter sequences
by means of their CpG content. They discovered that promo-
ters are either relatively depleted of CpG sites (low CpG
promoters, LCPs) or enriched in CpG sites (high CpG pro-
moters, HCPs), preferentially around the transcription start
site (TSS). Weber et al (2007) introduced a third class of
promoters called intermediate CpG promoters (ICPs), to
account for the overlap between the classes mentioned
above. They also developed precise classiﬁcation criteria for
the three classes, which we utilised in an adapted form: in
this study, we considered positions  700 to þ500 relative to
the TSS for the promoter classiﬁcation (cf. Materials and
methods), since both CpG density and differential DNA
methylation are distributed symmetrically around the TSS
(Saxonov et al, 2006). Figure 3C shows that most of the
differentially methylated CpG sites from T2D islets are lo-
cated in LCP and ICP class promoters. ICP class promoters
have been described as regions of dynamic DNA methylation
changes (Weber et al, 2007), while LCP class promoters have
seldomly been investigated. Their role as sites of hypomethy-
lation in T2D therefore remains to be explored.
Looking directly at the CpG ratio of the promoter se-
quences (cf. Materials and methods), the Inﬁnium array
resembles the distribution found in a comprehensive set of
human promoters (cf. Weber et al, 2007 and Figure 3D, red
bars). The CpG ratio of the promoters displaying differential
methylation in T2D islets (Figure 3D, blue bars) is clearly
distinct from the probes represented on the Inﬁnium array
and also contrasts with the CpG distribution found in pro-
moters throughout the genome. Following the distribution of
the blue bars in Figure 3D, it becomes apparent that most
DNA methylation proﬁling of type 2 diabetic islets
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depleted in CpG sites (CpG ratio o0.5) whereas only few
CpG-rich promoters gain or lose methylation in T2D islets.
In terms of genomic features, we third evaluated whether
the observed aberrant DNA methylation in T2D islets corre-
lated with speciﬁc regulatory elements. The use of computa-
tional approaches to extract functional meaning from the
annotated genome has gained importance in recent years.
Roider et al (2009) underscored the need to ﬁrst separate gene
promoters on the basis of their CpG content before analysing
the presence of enriched transcription factor-binding motifs.
These authors found that promoters depleted of CpG sites
often contain tissue-speciﬁc transcription factor-binding sites.
Therefore, we ﬁrst extracted CpG-depleted promoters by
selecting all differentially methylated promoters with a CpG
ratio lower than 0.5 (Saxonov et al, 2006). We then used the
extracted set of 172 CpG-poor promoters as a starting point to
detect putative transcriptional regulatory signals using the
Pscan (Zambelli et al, 2009) software and the TRANSFAC
transcription factor motifs database (Matys et al, 2006).
Figure 2 Validation of aberrantly methylated loci in T2D islets. (A) An exemplary locus, ALDH3B1, is shown. Methylation data for the
indicated CpGs obtained with the Inﬁnium assay as well as by conventional bisulphite sequencing (BS), and by bisulphite pyrosequencing
(BPS), are compared. Detected DNA methylation levels at other loci (B–D) are also in good agreement between the Inﬁnium methylation assay
(bar charts above the gene scale) and BPS used for validation (bar charts below gene scale) (see Supplementary Figure S4 for further
examples). CpG islands are indicated by a green line below gene scale. (E) Validation of the Inﬁnium DNA methylation data by BPS.
Methylation values obtained by Inﬁnium assay and BPS show high correlation (Pearson’s correlation coefﬁcient R¼0.927); (n¼3–8 for CTL;
n¼3–5 for T2D).
DNA methylation proﬁling of type 2 diabetic islets
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identiﬁed signiﬁcant enrichment of GATA transcription factor
family binding sites, namely GATA1 and GATA2 binding sites,
as well as a common binding site assigned to all GATA
proteins (P-values for enrichment ranged from 2.38 10
 15
to 3.28 10
 13; Supplementary Figure S5). We then repeated
this analysis using all differentially methylated LCP and ICP
promoters (cf. Supplementary Tables S2 and S3) to enlarge
the above mentioned set of 172 ‘CpG ratio o0.5’ promoters,
yielding similar results. To increase precision and to assess
validity of our predictions, we performed a negative control
by conducting the detection routine described above with 100
sets of 172 promoters randomly sampled from CpG-depleted
genes (CpG ratio o0.5) that are not differentially methylated
but present on the Inﬁnium array. Importantly, the highest
signiﬁcance of enrichment (best P-value) encountered in the
searches with these random gene promoter sets never ex-
ceeded the best P-value obtained with the set of differentially
methylated gene promoters (Supplementary Figure S5B).
Combined, these data reveal a statistically signiﬁcant enrich-
ment of GATA transcription factor-binding motifs in our set of
promoters (CpG ratio o0.5) differentially methylated in T2D
islets.
Differential DNA methylation observed in T2D islets
is not inducible by high glucose
The differential DNA methylation observed in T2D islets
might be either causative or instead secondary to the hyper-
glycaemia inherent to diabetes. Recent reports have shown
that transient exposure of aortic endothelial cells to high
glucose induced persistent epigenetic changes (DNA methy-
lation, H3K4 mono-methylation, H3K9/H3K16 acetylation;
El-Osta et al, 2008; Pirola et al, 2011). To determine whether
high-glucose stress modiﬁes DNA methylation in islets, we
exposed non-diabetic human islets to 28mM glucose for 72h
and subsequently analysed DNA methylation. Similar culture
conditions (30mM glucose, 48h) have been demonstrated to
result in determinate DNA methylation changes in vascular
cells (Pirola et al, 2011). We chose CpG sites that displayed
alterations in DNA methylation in T2D islets and which we
previously conﬁrmed by BPS (cf. Figure 2 and Supplementary
Figure S3). Islets from the same donor incubated for the same
duration at 6mM glucose served as control. As shown in
Figure 4A, the high-glucose treatment did not signiﬁcantly
affect DNA methylation of 16 CpGs in 13 gene promoters
tested, particularly in relation to the magnitude of DNA
Figure 3 Classiﬁcation of differentially methylated CpG sites and
regulatory element analysis of affected genes. (A) Classiﬁcation of
the CpG sites according to their location relative to CpG islands.
Most of the differentially methylated CpG sites are afﬁliated to genes
not possessing a CpG island or are 42kb away from the nearest
CpG island (termed ‘other CpGs’); only about one quarter of the
affected CpGs is located inside a CGI (‘CGI’) and about one quarter
is located in CGI shores (‘CGI shore’), that is, distance to the CGI is
between 1 and 2000bp. The observed distribution of differentially
methylated CpGs is signiﬁcantly different from that of the Inﬁnium
array (w
2 goodness-of-ﬁt test Po2.2 10
 16). (B) Representation as
bar plot with spatial resolution of the CGI shore shows that
differential methylation in CGI shores occurs predominantly close
to CGI borders (0–0.5 and 0.5–1kb). (C) Classiﬁcation of the
promoters afﬁliated to the CpG sites based on the promoter CpG
content. The observed distribution of promoter classes among
genes associated with differentially methylated CpGs is signiﬁcantly
distinct from that of the entirety of genes represented by CpG sites
on the Inﬁnium array (w
2 goodness-of-ﬁt test P¼7.1 10
 14) (for
numerical representation of classiﬁcations in A and C: cf.
Supplementary Table S3). (D) Direct plotting of CpG ratio (cf.
Materials and methods) shows T2D-associated differential methyla-
tion (blue bars) predominantly in low CpG density promoters.
(E) Prediction of putative TF binding sites using the set of low
CpG differentially methylated gene promoters (CpG ratio o0.5)
with the Pscan transcription factor motif analysis software.
Statistically signiﬁcant overrepresented binding sites have been
found for members of the GATA transcription factor family.
DNA methylation proﬁling of type 2 diabetic islets
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containing medium (28mM glucose for 72h). (A) Differences of DNA methylation in high glucose treated islets versus islets from the same
donor incubated under normal glucose conditions. The CpG sites analysed in this experiment correspond to the genomic positions interrogated
by the Inﬁnium assay that were demonstrated to display differential DNA methylation in T2D islets (cf. Figure 2 and Supplementary Figure S4).
Gene symbols listed twice represent genes with two Inﬁnium probes both of which were tested for glucose-induced differential DNA
methylation. Light and dark grey bars indicate two independent experiments. For comparison, the differences in DNA methylation in T2D
versus non-diabetic islets as determined by BPS are given (cf. Figure 2). (B) Three examples depicting BPS results in the two independent
experiments. (C) Global DNA methylation, as assessed by repetitive element LINE-1, shows no signiﬁcant changes after exposure of islets to
high glucose levels (norm. Glc: 6mM glucose in medium; high Glc: 28mM glucose in medium).
DNA methylation proﬁling of type 2 diabetic islets
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Figure 4B illustrates representative genes, namely SIRT6,
GRB10 and CHAC1, for which methylation changes measured
between islets exposed to high glucose and control islets were
minor compared with the absolute levels of methylation at
these positions. To assess global DNA methylation after high-
glucose stress, we analysed the repetitive LINE-1 element by
BPS. As shown above for the gene-speciﬁc methylation
changes, we did not ﬁnd signiﬁcant alterations in LINE-1
methylation between islets incubated under normal glucose
conditions and those exposed to high-glucose concentrations
(Figure 4C). Together, these ﬁndings suggest that the T2D-
related differential DNA methylation is probably not second-
ary to hyperglycaemia.
The T2D-related differential methylation pattern
is a feature of diseased islets
An important question regarding the differential DNA methy-
lation detected in T2D islets is whether these epigenetic
changes are unique for pancreatic islets or whether they are
part of a general pattern occurring in different tissues.
To examine this, we analysed peripheral blood leukocytes
from 12 T2D patients and compared their DNA methylation
proﬁles with 12 non-diabetic controls matched for age and
BMI (Supplementary Table S4). The two groups had signiﬁ-
cantly different glycaemia and HbA1c (Supplementary Table
S4). We quantiﬁed DNA methylation levels of 11 CpG loci in 9
gene promoters that exhibited differential methylation in T2D
islets and were validated by BPS (cf. Figure 2 and
Supplementary Figure S4). We detected no signiﬁcant differ-
ences in DNA methylation levels between control and T2D
blood samples in any of the 11 CpG loci analysed
(Supplementary Figure S6). This impelled us to examine
DNA methylation broadly, using again the Inﬁnium
Humanmethylation27 array already employed for the islets.
Differently from the islets, however, both groups displayed
very similar DNA methylation proﬁles (linear regression
R¼0.9989; Supplementary Figure S7A). As a matter of fact,
we detected almost no T2D-related differential DNA methyla-
tion in blood surpassing the cutoff (±15%, Po0.01). Only
one CpG locus in the promoter of the CIDEB gene showed
signiﬁcant hypermethylation (þ15.9%, P¼0.00066). CIDEB
inﬂuences obesity and liver steatosis and is a negative
regulator of insulin sensitivity (Li et al, 2007). Regarding
the 276 CpG loci differentially methylated in T2D islets, these
showed very limited DNA methylation changes between non-
diabetic and T2D blood cells (Supplementary Figure S7B).
In conclusion, the T2D-related DNA methylation changes
detected in pancreatic islets are essentially absent from whole
blood DNA. Indeed, we detected no T2D-related differential
methylation satisfying our signiﬁcance criterion except for a
single CpG in the promoter of CIDEB that, in turn, displays no
signiﬁcant differential DNA methylation in T2D pancreatic
islets. These data suggest that (1) the methylation pattern
observed in islets is apparently not a general phenomenon;
(2) blood is not a suitable surrogate tissue for studying T2D-
related epigenetic changes in pancreatic islets.
Differential DNA methylation can be correlated with
changes in gene expression in a subset of genes
Only few studies to date have reported gene expression
proﬁling in human pancreatic islets. An example of such
a study is the work by Bhandare et al (2010) that described
gene expression in islets from 31 non-diabetic donors. It was
of interest to examine whether the differential DNA methyla-
tion observed in our study occurred in promoters of ex-
pressed genes identiﬁed by Bhandare et al (2010) or
whether it was associated with inactive genes that may
become transcriptionally activated when hypomethylated.
By comparison of Entrez gene IDs, 196 genes (266 probes)
from the reported expression array could be matched to our
set of differentially methylated genes (for expression data cf.
Supplementary Table S2 columns AP ff.). Expression of all
matched genes was above background levels, asserting that
differential methylation occurs at promoters of genes that are
active in islets. As expected, their absolute expression levels
covered several orders of magnitude with no signiﬁcant
correlation between expression and promoter methylation
level (cf. Supplementary Table S2), that is, highly active
genes in islets are not necessarily devoid of DNA methylation
in their promoters. Our comparison of methylation and ex-
pression data therefore strongly suggests that the observed
changes in promoter DNA methylation levels are not restricted
to silent or lowly expressed genes but are also occurring in
promoters of expressed genes. In T2D islets, we observed
hypomethylation in the promoters of these active genes.
A recent study assessed gene expression in different islet
cell types including the insulin-producing b-cells (Dorrell
et al, 2011). A comparison showed that 240 of our 254
genes are covered by the microarray used by these authors.
In all, 170 of these genes have a positive presence call in
b-cells. This indicates that the majority of the genes we
detected as differentially methylated in T2D islets are ex-
pressed in non-diabetic b-cells to a sufﬁcient amount to be
reliably detected by microarrays, that is, these are genes
actively transcribed in b-cells.
We next examined whether the altered promoter DNA
methylation observed in T2D as compared with control islets
could be correlated with changes in gene expression. For this
purpose, we analysed gene expression in six islet prepara-
tions from male islet donors (three non-diabetic and three
T2D) using an Affymetrix HG-U133A microarray (cf.
Materials and methods). Of the 254 genes showing differen-
tial DNA methylation in T2D (cf. Figure 2, Supplementary
Figure S4 and Supplementary Table S2), 181 had associated
probes on the microarray, with a total of 320 matches
between Inﬁnium and expression assays (due to multiple
methylation or expression probes afﬁliated to the same genes;
Supplementary Table S4). Forty-one of these genes showed
signiﬁcant differential gene expression between CTL and T2D
islets (BH-adjusted Po0.05), of which about 80% (34 genes)
displayed an anticorrelation between changes in DNA methy-
lation and expression, for example, a decrease of DNA
methylation coinciding with an increase of expression
(Figure 5A and B; Supplementary Table S6). This suggests
that, at least for a subset of T2D-modiﬁed genes, changes in
the promoter DNA methylation correlate inversely with the
transcriptional activity of the gene. Regarding genomic
features, the distribution of the differentially methylated
CpGs in the promoters of these genes relative to the TSS is
similar to the distribution of all 276 differentially methylated
CpGs in our study (Supplementary Figure S8A). Also, the
distribution of promoter classes is comparable between the
254 differentially methylated genes and the subgroup
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sion (Supplementary Figure S8B; cf. also Figure 3B and
Supplementary Table S3).
The observation that only a subset of genes displays such
inverse correlation between DNA methylation and expression
changes could be partially explained by the fact that compar-
isons between promoter DNA methylation and expression of
the afﬁliated genes are often hampered by positioning of
array probes. For instance, the Inﬁnium array achieves an
average coverage of 1.9 CpG sites per promoter. However, due
to the occasionally high number of alternative promoters in
one gene, in most cases the Humanmethylation27 array does
not interrogate all promoters of a given gene (see Figure 5C
for examples). On the other hand, microarray probes are
mainly positioned in common exons that are present in most
or all alternative transcripts of a gene, thereby potentially
masking expression changes in one or few isoforms (Dai et al,
2005).
Consequently, our data are consistent with other studies
that were either unable to establish a connection between
Figure 5 Correlation between DNA methylation and gene expression changes in T2D islets. (A) Out of 41 genes that are differentially
methylated and differentially expressed (adjusted Po0.05; cf. Supplementary Table S4), 34 genes, E83%, show anticorrelation between
methylation and expression (33 are hypomethylated and overexpressed, PER2 is hypermethylated and its expression is decreased in T2D islets;
Supplementary Table S5) while 7 (E17%) show a positive correlation. (B) Boxplots of DNA methylation levels and gene expression in 41 genes
showing differential expression in T2D islets. Prevalent promoter hypomethylation is accompanied by overexpression of the associated genes.
(C) Three exemplative genes with indicated promoters, methylation probes and expression probes. ALDH3B1 methylation is measured at
promoter #2 and is correlated with expression data of a common exon that is present in all but one of the ALDH3B1 mRNAs. In case of
hypomethylation uniquely occurring at promoter #2 (promoters #1 & #3 are not interrogated by the Inﬁnium assay), the effect of this promoter
hypomethylation on gene expression would be abated by the unchanged expression of isoforms transcribed from the other two promoters. In
the case of PER2, methylation at promoter #1 and expression of the long isoform is assessed. *There are several Affymetrix probes for CASP10
that demonstrate differential expression but fail to reach the signiﬁcance criterion of Po0.05 (BH-corrected P of Student’s t-test; cf.
Supplementary Table S4).
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(Illingworth et al, 2008) or found a small but signiﬁcant set
of genes with anticorrelation between changes in promoter
methylation and gene expression (Rakyan et al, 2008). Our
work is thus in agreement with the emerging notion that, for
most genes, the methylation–expression relationship cannot
be broken down to the simple formula that decreased methy-
lation equals elevated expression (Eckhardt et al, 2006;
Illingworth et al, 2008; Suzuki and Bird, 2008).
Biological pathways associated with differential DNA
methylation in diabetic islets: at least some of the
uncovered differentially methylated genes possess
pathophysiological signiﬁcance for b-cell function
To determine the biological relevance of the differential DNA
methylation in pancreatic islets, we followed a two-winged
strategy consisting of a combined computational and litera-
ture approach on one hand, and on the other hand in-vitro
experiments to uncover the functions of genes that were
previously unknown in the context of pancreatic islets and/
or b-cells.
For the ﬁrst approach, we assessed whether the differen-
tially methylated genes have any overlap or other association
with known T2D risk genes. Then, we carried out an
Ingenuity Pathway Analysis (IPA; Figure 6A) to identify
pathways that are epigenetically affected in T2D islets accord-
ing to our methylation proﬁling data. This was augmented by
a manual search for the differentially methylated genes in
scientiﬁc literature reporting on the general biology as well as
T2D-related functions of these genes or the pathways they are
part of (Figures 6 and 7). For the second approach, we
knocked down expression of several genes by RNA interfer-
ence and tested the functional consequence of their depletion
in b-cells (Figure 8). For two selected genes, we explored their
functional role more extensively in isolated b-cells and
human islets (Figure 9).
At the outset, we analysed the differentially methylated
genes with regard to their reported functions and the biolo-
gical pathways they are part of. To date, large-scale GWAS
have uncovered a number of T2D susceptibility loci (Saxena
et al, 2007; Scott et al, 2007; Sladek et al, 2007; Zeggini et al,
2007, 2008). Several of these genes have a role in b-cells.
Therefore, we compared our data with the known T2D risk
Figure 6 Biological pathways associated with differentially methylated loci. (A) Ingenuity pathway analysis reveals canonical pathways
signiﬁcantly enriched in T2D pancreatic islets. Measure of signiﬁcance is indicated by Benjamini-Hochberg-corrected P-value (abbreviated as
‘BH P-value’ in the x axis label of the depicted chart). (B) Manual curation of the biological functions associated with the differentially
methylated genes unravelled three broad categories of cellular responses that might be affected in T2D islets. Some of these genes are part of
processes leading to b-cell dysfunction and cell death while others seem to facilitate b-cell survival and adaptation to the T2D environment.
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epigenetic dysregulation. None of the established T2D sus-
ceptibility loci (Voight et al, 2010) revealed signiﬁcant differ-
ential DNA methylation in our analyses. The only gene
previously detected in GWAS as a potential T2D-associated
locus is GRB10 (Di Paola et al, 2006; Rampersaud et al, 2007),
an imprinted gene (cf. Supplementary data) that displays
hypomethylation in diabetic islets (Supplementary
Figure S4L). We did ﬁnd aberrantly methylated genes with
similar biological functions to the known T2D susceptibility
genes (Supplementary Table S2). For example, KCNQ1 and
KCNJ11 (SNP variants of which are associated with higher
T2D incidence; Scott et al, 2007) were not signiﬁcantly altered
in their methylation levels but three other potassium channel
genes, KCNE2, KCNJ1 and KCNK16, had changed promoter
methylation states (Supplementary Table S2). Other examples
   1. Dysfunction/cell death-associated functions 
DNA damage/oxidative stress
ALDH3B1 encodes an aldehyde dehydrogenase that can protect cells from lipid peroxidation-induced cytotoxicity (Marchitti et al, 2007). (Figure 2A) 
GSTP1 plays an important role in detoxification by catalysing the conjugation of many hydrophobic and electrophilic compounds with reduced glutathione. GSTP1
Ile105Val polymorphism has been associated with diabetic renal insufficiency (Tiwari et al, 2009).  
Endoplasmic reticulum (ER) stress
NIBAN is induced during ER stress and may counteract the suppression of protein translation that occurs under this condition (Sun et al, 2007). (Figure S4G) 
CHAC1 is also induced by ER stress (as part of the unfolded protein response, UPR) but its induction may trigger apoptosis (Mungrue et al, 2009). (Figure S4K) 
Apoptosis
NR4A1 is involved in ER stress-induced apoptosis and can interact with the antiapoptotic protein BCL2 (Contreras et al, 2003; Liang et al, 2007). (Figure S4H) 
MADD, encoding MAP-kinase activating death domain-containing protein that has an anti-apoptotic function, was found to be hypermethylated in this study. 
Besides its role in apoptosis protection (Kurada et al, 2009), it may play a role in glucose homeostasis (Dupuis et al, 2010). (Figure S4F) 
CASP10 is involved in advanced-glycation-end product-induced apoptosis (Lecomte et al, 2004; Obrenovich and Monnier, 2005) and can activate NF-κB (Wang 
et al, 2007). The CASP10 gene is absent in the mouse and rat genome; both species are frequently used as T2D model organisms (Janicke et al, 2006; Reed 
et al, 2003). (Figure 2B) 
   2. Adaptation-associated functions 
Signal transduction
MAPK1 is an important regulator of β-cell function (Lawrence et al, 2008), for example contributing directly to short-versus  long-term insulin response and
regulation of pro-apoptotic CHOP10 (Lawrence et al, 2007). MAPK1 constitutes the center of a regulatory network implicated in elevated free fatty acid  (FFA)
levels (Sengupta et al, 2009) common in T2D patients. MAPK/ERK signalling is exacerbated by FFA that lead to dephosphorylation of cascade proteins by
PP2A/PPP2R4 (Guo et al, 2010) pointing towards a certain level of interwovenness between the identified processes, in this case signal transduction
(adaptation category) and ER stress (dysfunction/cell death category, cf. Figure 5B). (Figure 2C)  
CDK5R1 acts as an activator of CDK5 (Ubeda et al, 2004) whose expression is regulated by glucose and which inhibits insulin secretion (Wei et al, 2005).
Hyperglycaemia-caused overactivation of CDK5 may contribute to β-cell glucotoxicity (Ubeda et al, 2006). (Figure S4C) 
Hormones, growth factors
The growth factor EGF has been shown to increase β-cell mass in human pancreatic islets in vitro and in vivo (Suarez-Pinzon et al, 2005a, b) and protect against 
oxidative stress (Maeda et al, 2004). FGF1 stimulates β-cell differentiation (Oberg-Welsh and Welsh, 1996) while its experimental attenuation has been shown to
induce diabetes (Hart et al, 2000). 
The hypomethylated CpG detected in the insulin-like growth factor 2 (IGF2) locus (Keller et al, 2008), which is situated in a large open chromatin domain
(Mutskov and Felsenfeld, 2009), is located inside a CpG island between exons 3 and 4, which translates to a position inside IGF2AS according to the Infinium array
probe annotation. Interestingly, this hypomethylated CpG island is also present in the mouse homolog juxtaposed to Igf2 DMR1. We speculate that this differential 
DNA methylation may influence the regulation of one or several isoforms of IGF2. Moreover, as IGF2AS has been described as a paternally imprinted antisense 
transcript of IGF2, there is a possibility that the differential DNA methylation could lead to altered IGF2AS expression thereby dysregulating IGF2. (Figure 2D)  
Transcription factors
FOXA2 (HNF3B) is part of a transcription factor network regulating β-cell differentiation (Lee et al, 2002; Sund et al, 2001).  
PAX4 promotes β-cell proliferation and is antiapoptotic in human islets  (Brun et al, 2004), while  SOX6 inhibits proliferation (Iguchi et al, 2007); both 
transcription factors can affect β-cell function (Iguchi et al, 2005). 
SIRT6 has been shown to be induced upon nutrient deprivation (Kanfi et al, 2008; Kawahara et al, 2009; McCord et al, 2009; Michishita et al, 2009) and might 
be associated with maintenance of genomic stability and prevention of senescence/cell loss of islet cells (Mostoslavsky et al, 2006), possibly through attenuation
of NF-κB signalling (Kawahara et al, 2009). (Figure S4I) 
Metabolism
Among the few differentially methylated metabolism-related genes were HK1 and FBP2, both of which are induced in diabetic islets and negatively affect glucose-
induced insulin secretion (Kebede et al, 2008; Malmgren et al, 2009). 
CDO1 catalyses the first step in the major cysteine catabolism pathway (Stipanuk et al, 2006). Its hypermethylation could lead to an elevated intracellular cysteine 
concentration which inhibits insulin secretion (Kaneko et al, 2006) but might promote glutathione synthesis (Williamson et al, 1982) (cf.GSTP1) thus protecting 
cells from oxidative stress. However, inhibition of CDO1 pathway-facilitated taurine synthesis may counterbalance that effect (Anuradha and Balakrishnan, 1999).
(Figure S4B)  
Figure 7 Biological functions of differentially methylated genes in T2D islets from the existing literature. Biological functions are highlighted
for a selection of the differentially methylated loci that we hypothesise to play important roles in diabetic islets. Note that several genes
involved in different processes can negatively affect insulin secretion. The referenced ﬁgures at the end of the descriptions of several genes
depict the methylation analyses of these genes’ promoters.
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related functions are SLC30A8 and CDKAL1. In our data sets,
SLC30A8 was not differentially methylated but two other zinc
transporter genes, SLC39A5 and ZIM2, were hypomethylated.
For CDKAL1 we found its methylation state unchanged in
T2D islets, while its target gene CDK5R1 exhibited pro-
nounced hypomethylation (Supplementary Figure S4C).
In summary, although the promoter methylation of estab-
lished T2D susceptibility loci was unchanged in our proﬁling
approach, other genes with similar biological function (e.g.,
potassium and zinc transporters) or part of the same regula-
tory networks (e.g., CDK5R1 in the CDK5 pathway and GRB10
in the insulin signalling pathway) displayed aberrant DNA
methylation.
The analyses described above found only few common
T2D candidate genes among the differentially methylated
genes uncovered in this study. This could imply that T2D
pathogenesis in islets is partially mediated by previously
unappreciated genes. To decipher their roles in the context
of T2D islets, as a ﬁrst step we performed an IPA to determine
which canonical pathways were overrepresented in our set of
genes (Figure 6A). Inﬂammation-related processes were
highly enriched, in particular the acute phase response and
IL-8 signalling. Other enriched pathways, such as apoptosis
and death receptor signalling, emphasise the role of b-cell
loss in T2D. Enrichment for pathways involved in metabo-
lism and internal and external cell structure (e.g., actin
cytoskeleton and integrin signalling) may be indicative of
altered islet function and architecture.
Second, we performed an extensive manual curation
according to a previously described b-cell-targeted annotation
(Kutlu et al, 2003; Ortis et al, 2010). In partial agreement with
the IPA, we found these genes to fall into three broad
categories: (1) genes related to b-cell dysfunction and
death, (2) genes potentially facilitating the adaptation of the
pancreatic islets to the altered metabolic situation in T2D and
(3) genes whose role in disease pathogenesis remains to be
unearthed (Figure 6B). The adaptation-related gene category
contains few metabolism-associated genes (e.g., HK1, FBP2;
Figure 6B, right part, Figure 7) and many more genes
involved in signal transduction or encoding hormones,
growth factors (e.g., EGF, FGF1, IGF2/IGF2AS; Figure 7), or
transcription factors involved in important regulatory net-
works (for instance, FOXA2/HNF3B, PAX4 and SOX6)
(Figure 6B, right part, Figure 7). In the b-cell dysfunction
and death category, there were hypomethylated genes related
to DNA damage and oxidative stress (e.g., GSTP1, ALDH3B1;
Figure 7), the endoplasmic reticulum (ER) stress response
(NIBAN, PPP2R4, CHAC1), and apoptosis (CASP10, NR4A1,
MADD; Figure 6B, left part, Figure 7).
Some genes of interest from the highlighted categories are
depicted in Figure 7. Their annotated functions provide
possible explanations of how the epigenetic dysregulation
of these genes in diabetic islets is connected to T2D patho-
genesis. Numerous genes that were identiﬁed by our methy-
lation proﬁling approach have been functionally implicated
in insulin secretion. Examination of the available literature on
the function of these genes revealed three aspects of insulin
secretion with which they interfere: some of these genes
inﬂuence the expression of the insulin gene, like MAPK1
and SOX6, or its post-translational maturation, like PPP2R4
(cf. Figure 7 and references therein). Others can deregulate
the process of insulin secretion itself (SLC25A5, Ahuja et al,
2007; RALGDS, Ljubicic et al, 2009) or inﬂuence synthesis as
well as secretion (vitronectin, Kaido et al, 2006). A third
group of differentially methylated genes affects (i) signalling
processes in the b-cell leading to insulin secretion or (ii)
glucose homeostasis in b-cells, thereby modulating insulin
response upon stimulation. GRB10 (Yamamoto et al, 2008),
FBP2 and HK1 (Figure 7) are examples for these genes.
Additional genes found in our study have been implicated
in the b-cells’ capability to secrete insulin, though the me-
chanisms have not yet been fully established. The putative
functions of these genes indicate a potential epigenetic
impact on insulin secretion at multiple levels, namely signal-
ling, expression/synthesis and secretion.
Functional analysis of differentially methylated genes
reveals their involvement in speciﬁc biological
processes in islets and b-cells
We next sought to provide experimental proof that altering
the activity of some of the differentially methylated genes
translates into functional effects that impinge on b-cell via-
bility. We ﬁrst performed a screening for cellular outcome
after knockdown of eight selected differentially methylated
genes. b-Cell survival was examined under basal conditions
and after exposure to the saturated fatty acid palmitate or the
ER stress-inducer cyclopiazonic acid (CPA, a speciﬁc inhibitor
of the sarcoendoplasmic reticulum Ca
2þ ATPase pump
(SERCA; Pahl et al, 1996)) following silencing of MKNK2
(MAP kinase-interacting serine/threonine kinase 2 isoform
2), GUCA2B (guanylate cyclase activator 2B), PER2 (period
isoform 2), SFRS2IP (splicing factor arginine/serine-rich 2,
interacting protein), NR4A1, BCL2, CHAC1 and NIBAN
by RNA interference (Figure 8). Knockdown of BCL2,a n
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Figure 8 Screening of biological function of eight differentially
methylated genes in b-cells. Cell death was evaluated in INS-1E
cells transfected with different speciﬁc siRNAs and treated 2 days
later with 0.5mM palmitate or 25mM CPA for 16h (n¼3–7).
siRNAs were used targeting Mknk2 (MAP kinase-interacting ser-
ine/threonine kinase 2), Guca2b (guanylate cyclase activator 2B),
Per2 (period homologue 2), Sfrs2ip (splicing factor, arginine/serine-
rich 2, interacting protein), Chac1 (ChaC, cation transport regulator-
like 1), Nr4a1 (nuclear receptor subfamily 4, group A, member 1),
Bcl2 (B-cell lymphoma 2) and Niban. Cell survival was measured by
neutral red staining and data were expressed as cell death relative to
cells transfected with negative siRNA (siCTL) and cultured under
control condition (CTL). *Po0.05 against cells under the same
treatment transfected with siCTL,
#Po0.05 as indicated.
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immediate-early response gene, and MKNK2, a kinase that
functions downstream of p38 and ERK, controlling cell
survival and negatively regulating global protein synthesis,
resulted in increased basal cell death in the rat b-cell line INS-
1E (Figure 8). NR4A1, BCL2 and NIBAN also were antiapop-
totic under lipotoxic conditions, as their knockdown sensi-
tised b-cells to palmitate. Four of the selected genes exerted
proapoptotic functions in b-cells, illustrated by the improved
survival following their knockdown and palmitate or CPA
exposure. These were the clock gene PER2, GUCA2B, a ligand
for guanylate cyclase receptor C that transduces signals for
insulin secretion and growth and differentiation, SFRS2IP,a
protein required for pre-mRNA splicing, and CHAC1.
The biological role of two of these differentially methylated
genes with previously unknown function in b-cells, namely
NIBAN and CHAC1, was further studied. NIBAN and CHAC1
have been suggested to be part of the ER stress response in
other cell types (Sun et al, 2007; Mungrue et al, 2009). Such
ER stress response can initiate apoptosis and has been
implicated in b-cell demise in diabetes (Eizirik et al, 2008).
To explore the role of NIBAN and CHAC1 in ER stress in
greater depth, human islets were treated with the physiolo-
gical ER stressors oleate and palmitate (Cunha et al, 2008) or
Figure 9 Role of differentially methylated NIBAN and CHAC1 in b-cell apoptosis. (A) NIBAN mRNA expression in human islets treated for 24h
with oleate or palmitate (left panel) and with synthetic ER stressors thapsigargin (THA), tunicamycin (TUN) or brefeldin (BRE). CTL denotes
control. Results represent mean±s.e. of 3–5 independent experiments. (B) Niban mRNA expression in rat INS-1E cells transfected with
negative siRNA (siCTL) or Niban siRNA (siNiban) and treated for 16h with palmitate or cyclopiazonic acid (CPA). Results represent mean±s.e.
of 3–4 independent experiments. (C) Percentage of apoptosis in siRNA-transfected INS-1E cells after 16h of palmitate or CPA treatment. Lower
panel: western blot quantiﬁcation of cleaved caspase 3 as an additional apoptosis marker. The blot is representative of four independent
experiments. (D) CHAC1 mRNA expression in human islets treated for 24h with oleate or palmitate (left panel) and with synthetic ER stressors.
Results represent mean±s.e. of 3–5 independent experiments. (E) Chac1 mRNA expression in rat INS-1E cells transfected with negative siRNA
(siCTRL) or Chac1 siRNA (siChac). (F) Apoptosis in siRNA-transfected INS-1E cells after 16h of palmitate or CPA treatment. Results represent
mean±s.e. of 4–10 independent experiments. Lower panel: western blot quantiﬁcation of cleaved caspase 3 as an additional apoptosis marker.
The blot is representative of four independent experiments. *Po0.05 against untreated (CTL) cells,
#Po0.05 by paired ratio t-test.
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(TUN) or brefeldin (BRE). Expression of NIBAN was induced
about two-fold by the saturated fatty acid palmitate
(Figure 9A, column 3) but not with oleate (Figure 9A,
column 2), which is a less potent inducer of ER stress
(Cunha et al, 2008). A similar induction of expression was
observed for CHAC1 when islets were treated with palmitate
(Figure 9D, column 3) but not with oleate (Figure 9D, column
2). The synthetic ER stressors THA, TUN and BRE also
increased NIBAN and CHAC1 mRNA expression in human
islets (Figure 9A and D, right panels). THA, which causes ER
calcium depletion by blocking the SERCA pump (Pahl et al,
1996), TUN, which blocks glycosylation of nascent proteins
(Hickman et al, 1977), and especially BRE, which inhibits ER-
to-Golgi transport (Misumi et al, 1986), induced NIBAN and
CHAC1 gene expression. The magnitude of ER stress induced
by these three chemicals and palmitate, as measured by
ATF3, CHOP and BiP mRNA expression (Supplementary
Figure S9), was closely correlated with the NIBAN and
CHAC1 induction.
We next determined the functional role of NIBAN and
CHAC1 expression on the outcome of ER stress in b-cells.
For this purpose, we exposed INS-1E cells to palmitate or
CPA. ER stress induced by these agents increased Niban
mRNA expression (columns 1, 3, 5 in Figure 9B). As shown
in Figure 9B, expression of Niban is efﬁciently diminished by
a speciﬁc small interfering RNA (siRNA) (siNiban; compare
columns 1 and 2, 3 and 4, 5 and 6). RNAi-mediated knock-
down of Niban increased apoptosis induced by palmitate
(Figure 9C; columns 3 and 4) as well as by CPA (columns 5
and 6 in Figure 9C). This is mirrored by an elevated caspase 3
activation (Figure 9C, lower panel). Taken together, the
increase of Niban expression during ER stress and augmented
apoptosis after its knockdown indicates an antiapoptotic role
for Niban during the b-cell ER stress response.
Chac1 mRNA expression was also induced by palmitate
and CPA in INS-1E cells (Figure 9E). Chac1 knockdown by
siRNA (siChac) signiﬁcantly reduced its expression upon
incubation with palmitate (Figure 9E, columns 3 and 4) or
with CPA (columns 5 and 6 in Figure 9E). We next analysed
whether the knockdown of Chac1 affected ER stress-induced
apoptosis stimulated by palmitate and CPA (Figure 9F). We
found that Chac1 knockdown protected b-cells from apopto-
sis (cf. columns 3, 4 and 5, 6 in Figure 9F), which was
conﬁrmed by a lessened activation of caspase 3 (Figure 9F,
lower panel). The induction of Chac1 expression by ER
stressors and the fact that its knockdown protected b-cells
from ER stress-induced apoptosis suggest that Chac1 is
involved in apoptosis triggered after the different branches
of ER stress response fail to re-establish ER homeostasis
in b-cells.
These experiments investigated two novel genes with
opposite effects on ER stress-induced apoptosis in human
islets, CHAC1 and NIBAN. Expression of both genes is
strongly induced by ER stress, elicited by different agents.
While NIBAN protects b-cells against apoptosis, the activation
of CHAC1 indicates failure of the processes restoring b-cell
functionality and heralds ER stress-induced apoptosis (Eizirik
et al, 2008; Eizirik and Cnop, 2010).
In conclusion, by looking at genes known to be involved in
T2D/islet pathology as well as by loss of function experi-
ments, our analyses indicate that we did not pick up some
irrelevant variations in DNA methylation levels but that the
uncovered epigenetic changes indeed affect genes vital for
b-cell function and survival. These genes might therefore be
important, and provide previously unappreciated players in
T2D pathogenesis.
Discussion
In this study, we performed the ﬁrst comprehensive DNA
methylation proﬁling of human T2D pancreatic islets identi-
fying 276 differentially methylated CpG sites that are
afﬁliated to 254 genes. These generated data illustrate, for
the ﬁrst time, the epigenetic dimension of T2D in islets and
how this is associated with transcriptional alterations. The
pathophysiological signiﬁcance of eight genes found to be
differentially methylated in their promoters was validated by
RNAi experiments.
It has been suggested that progressively occurring DNA
methylation errors lead to diminished gene responsiveness to
external stimuli and might thus contribute to the develop-
ment of T2D (Gallou-Kabani and Junien, 2005). Our ﬁndings
of prevalent promoter hypomethylation in T2D islets are
indicative of active biological processes involved in adapta-
tion to the diabetic environment as well as biological path-
ways associated with b-cell dysfunction and apoptosis
(Figures 6B and 7). The functional relevance of some of the
differentially methylated genes in b-cells was documented by
screening for b-cell survival/death following RNAi and sub-
sequent exposure to stresses relevant to T2D (Figure 8).
Given the increased evidence that ER stress-induced apopto-
sis is one of the mechanisms of b-cell loss in T2D (Eizirik
et al, 2008), it was of interest to further assess the biological
functions of two putative ER stress-related genes that we
found to be hypomethylated in T2D islets, namely NIBAN and
CHAC1. We observed that these two genes are upregulated by
synthetic ER stressors and by the more physiologically rele-
vant saturated fatty acid palmitate in human islets, while
knockdown of their expression by speciﬁc RNAi demon-
strated their modulatory role in apoptosis (cf. Figure 9).
While NIBAN protects against ER stress-induced apoptosis,
CHAC1 seems to contribute to cell death. The hypomethyla-
tion observed at both genes could be explained by competing
proapoptotic and antiapoptotic processes during ER stress
response in diabetic islets. NIBAN is a negative regulator of
translation initiation factor eIF2a (Sun et al, 2007). Therefore,
its hypomethylation may indicate an attempt to re-establish
ER homeostasis by reduction of protein synthesis (Eizirik
et al, 2008). Pending the outcome of these attempts, ER
stress-induced apoptosis may be triggered by CHAC1 and
other proapoptotic genes.
An important question with regard to epigenetic changes
is: are the observed DNA methylation changes reﬂected in
gene activity? By comparing the obtained DNA methylation
proﬁles with microarray gene expression data, we were able
to determine that a high proportion of genes in whose
promoter T2D-related differential DNA methylation occurs
are actively transcribed in pancreatic islets. A comparison
with expression data of islet cell types (Dorrell et al,2 0 1 1 )
showed that most of the differentially methylated genes are
expressed in b-cells. This allowed us to conclude that T2D-
related aberrant DNA methylation partially happens in the
promoters of active genes. One has to keep in mind though
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analysed non-diabetic material. We observed mostly DNA
hypomethylation in diabetic islets, not infrequently accom-
panied by elevated gene expression. Therefore, it can be
assumed that the T2D-related hypomethylation leads, in
part, to the induction of formerly silent genes.
Regarding differential gene expression in T2D islets, we
observed an inverse correlation between differential promo-
ter methylation and differential gene expression for a subset
of genes. It is worth mentioning that for a signiﬁcant propor-
tion of differentially methylated genes, no statistically sig-
niﬁcant differential expression was observed (compare
Supplementary Tables S4 and S5). This may partially be
due to the incompatibilities between methylation assays
and the design of expression microarrays mentioned above
that hamper in-depth comparisons between methylation and
expression. However, for many genes the link between
differential methylation and gene activity may be quite com-
plex. Methylation of the cytosine base changes the topology
of the major DNA groove, which may affect the binding of
many transcription factors and DNA-binding proteins.
Supporting this possibility, binding of two transcription fac-
tors whose target genes are differentially methylated in T2D
islets has been described as methylation sensitive, namely
CTCF (which binds to IGF2/IGF2AS, Bell and Felsenfeld,
2000; Filippova et al, 2005) and YY1 (which binds to ZIM2,
Kim et al, 2003). Additionally, we found several genes
encoding chromatin-associated proteins and transcription
factor genes differentially methylated in T2D islets (cf.
Figure 6B and Supplementary Table S2). Should the expres-
sion of these genes and/or their binding motifs be inﬂuenced
by differential DNA methylation in T2D islets, it might further
add to the complexity of the methylation–expression relation-
ship. This could potentially explain the observations made in
this study as well as others (Eckhardt et al, 2006; Illingworth
et al, 2008; Suzuki and Bird, 2008) that the relationship
between DNA methylation and gene expression is rather
complex.
In terms of genomic features, we detected T2D-associated
differential DNA methylation mainly in LCP and ICP, while
HCPs are underrepresented. Analysing LCP and a subset of
ICP genes (CpG ratio o0.5), we discovered GATA family
transcription factors that are predicted to regulate a signiﬁ-
cant subset of these genes. Interestingly, the GATA transcrip-
tion factor family members are critical regulators in
endocrine development, function and pathologies (Viger
et al, 2008). The physiological roles of many differentially
methylated loci in T2D can be described as genes responding
to (external) stimuli and to stress. Of note, Saxonov et al
(2006) found that a disproportionately high percentage of
genes afﬁliated to these biological functions possess promo-
ters with a low CpG density. This might indicate a general
principle with regard to the promoter class of the differen-
tially methylated gene loci: while in chronic diseases such as
T2D and lupus (Javierre et al, 2010) LCP genes are over-
represented, in diseases associated with cellular overgrowth
(such as cancer) there is increased prevalence of HCP and
relatively few LCP genes (Richter et al, 2009; Martin-Subero
et al, 2009a, b). Further studies are required to test this
intriguing possibility.
A key issue is whether the methylation changes we report
play a causal role in T2D or are secondary to the diabetic
condition. Indeed, the hypomethylation observed in oxidative
stress, ER stress and apoptotic pathways may result from
chronic exposure to the stressful metabolic environment of
T2D, for example, high-glucose concentrations (Cnop et al,
2005). An interesting example in this respect is CASP10:
we found signiﬁcant hypomethylation in its promoter
(Figure 2B) and since caspase 10 is inducible by advanced
glycation end products (Lecomte et al, 2004; Obrenovich and
Monnier, 2005), this hypomethylation could be indicative of
gene activation caused by chronically elevated blood glucose
levels and consequently heightened non-enzymatic glycosy-
lation events. Interestingly, experimental exposure of islets
from non-diabetic donors to high-glucose concentrations
(28mM) for 72h did not induce differential DNA methylation
in any of the genes that display methylation changes in T2D
islets. Even though these ﬁndings do not exclude an impact of
chronic exposure to stressors like hyperglycaemia on the islet
epigenome, they do make it unlikely that the observed
alterations in DNA methylation are merely a consequence
of relatively short metabolic insults. By inferring from the
functions of the differentially methylated genes, it is possible
that some of the identiﬁed epigenetic changes play a role in
the progressive islet dysfunction in T2D, that is, they have
potentially been acquired at different time points during
pathological decline. Thus, the hypomethylation observed
at some genes, like CASP10, may be a consequence of T2D
and severe and long-lasting hyperglycaemia. On the other
hand, some genes, for example, those related to insulin
secretion, may have obtained alterations in promoter methy-
lation much earlier. For instance, defects in acute insulin
response to glucose (AIRg) are among the earliest impair-
ments and even precede the onset of pre-diabetic IGT
(Bogardus and Tataranni, 2002; Fukushima et al, 2004;
Leahy, 2005; Bunt et al, 2007). If aberrant AIRg arises from
epigenetic aberrations at genes involved in insulin secretion
(which is an established function for many genes in our
study), these defects should manifest ahead of clinical T2D
development. Whether such changes can be designated ulti-
mately causal for the decline into T2D will remain to be
proven. Overall, from the data at hand the changed methyla-
tion in the promoters of some genes identiﬁed in our study
might thus be consequential and represent reactions to the
diabetic environment. At other genes, the methylation aber-
rations could be interpreted to play a causal role, driving the
islet dysfunction and T2D pathogenesis. Future, large-scale
studies involving multiple stages of T2D development will be
needed to elucidate the role of the epigenetic changes in the
various stages of T2D pathogenesis. Due to medical ethics, it
is impossible to obtain repeated pancreatic biopsies.
Therefore, these studies will need to rely on surrogate tissues
that remain to be validated. The availability of the presently
described human islet methylation proﬁling will allow future
search and validation of surrogate tissues.
However, identiﬁcation and validation of tissues whose
T2D-related DNA methylation proﬁles can serve as a proxy
for pancreatic islets might prove difﬁcult. The apparent
absence of signiﬁcant T2D-related differential DNA methyla-
tion in blood raises the possibility that T2D-related epigenetic
aberrations are tissue-speciﬁc although more tissues will
have to be screened to substantiate this. The ﬁnding of almost
no differential DNA methylation in blood cells of T2D
patients versus the signiﬁcant changes in pancreatic islets
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ence is attributable to the different lifespan of the cells, for
blood cells being days to months while b-cells have a lifespan
of many decades (Cnop et al, 2010). The validity of blood
for epigenetic analysis has, however, been established by
previous studies that uncovered differential methylation in
DNA isolated from whole blood of individuals that were
prenatally exposed to famine (Heijmans et al, 2008; Tobi
et al, 2009). Further investigations into T2D-related epige-
netic changes in surrogate tissues for pancreatic islets might
elucidate their causative role or expose them as consequences
of the disease.
A possible confounding factor for the identiﬁcation of T2D-
related epigenetic proﬁles is the medication that T2D patients
receive and that may inﬂuence gene regulation. Histone
deacetylase inhibitors (HDACi), for example, have been de-
monstrated to increase insulin sensitivity in muscle and liver
and partially thwart diabetic nephropathy and retinopathy
(Christensen et al, 2011). It is possible that diabetes drugs like
rosiglitazone, a PPAR-g agonist, or metformin will alter gene
activity patterns and confound proﬁling approaches.
Adequately powered epigenetic proﬁling studies of surrogate
tissues that consider the patients’ medication may yield new
insight of relevance for drug-based T2D therapy.
As acknowledged by McCarthy and Zeggini (2009), the
440 gene variants of T2D susceptibility genes known to date
cannot fully explain T2D predisposition. Our study points to
the involvement of epigenetic alterations in T2D thus under-
scoring the previously established contribution of lifestyle
habits to its development. Combining the advantages of
genome-scanning techniques and epigenome analyses might
pave the way to better comprehend the pathogenesis of T2D.
It will be of great interest to examine SNPs in the differen-
tially methylated genes in T2D described in this study since
the interplay between SNPs and differential (allele-speciﬁc)
DNA methylation has recently been described (Shoemaker
et al, 2010). Linked to the topic of allele-speciﬁc DNA
methylation, it is noteworthy that a number of the genes
found to display differential methylation are also reported to
be imprinted (Supplementary data). It could hence be specu-
lated that at least a partial loss of imprinting occurs in T2D
islets.
In conclusion, we report the ﬁrst comprehensive and
detailed analysis of epigenetic changes in T2D, speciﬁcally
an altered DNA methylation proﬁle in the pancreatic islets of
T2D patients with a major preponderance of hypomethyla-
tion in sequences outside CGIs. These aberrant methylation
events affect over 250 genes, a subset of which is also
differentially expressed. The dysregulation of these genes in
T2D may notably be linked to b-cell functionality, cell death
and adaptation to metabolic stress. Examination of two genes
identiﬁed by methylation proﬁling, NIBAN and CHAC1,
revealed their biological functions in distinct processes of
the ER stress response. Furthermore, our data highlight genes
belonging to biological processes whose involvement in T2D
is not yet fully understood, such as inﬂammation and ion
transporters/channels/sensors. Importantly, it can be envi-
saged that the uncovered DNA methylation changes might be,
on one part, indicative of reactions of the islet cells to the
diabetic condition and on another part, might be causal of
T2D. A challenge in the future is to provide further evidence
for the primary effects of methylation changes in the diabetic
condition. Taken together, our DNA methylation study
on human islets thus lays the ground to further unravel the
biological complexity of T2D and outlines an unexpected
level of epigenetic regulation in islets, which must be taken
into account in future studies aiming to understand the
pathogenesis of T2D.
Materials and methods
Isolation of pancreatic islets
From September 2004 to November 2009, pancreatic islets of
Langerhans were isolated from pancreata of 5 T2D and 11 non-
diabetic male cadaveric donors in Pisa, Italy, with the approval of the
local Ethical Committee, and as described previously (Del Guerra
et al, 2005). Glucose-induced insulin secretion was measured as
described. The diagnosis of T2D was based on the previously
described clinical criteria (ADA, 1997; Genuth et al, 2003).
Islet purity and b-cell content
Reliable purity assessment for diabetic islets is challenging. In T2D,
the degranulated b-cells contain less insulin and zinc (Ostenson
et al, 2006) and the qualitative dithizone assessment (which targets
zinc) therefore underestimates T2D islet purity. Hence, we used EM
to analyse islet purity in some of the samples used in the
methylation proﬁling after 42 days in culture (Supplementary
data; n¼3 for T2D and non-diabetic samples, respectively) as
described (Welsh et al, 2005).
Blood sampling
After obtaining written informed consent, blood was sampled from
12 male T2D patients and 12 male age- and BMI-matched controls
in K2EDTA tubes.
Methylation proﬁling using the Inﬁnium assay
Genomic DNAs were isolated from pancreatic islets using the
Wizard
s SV Genomic DNA kit (Promega Corp.) and from 200mlo f
blood using the QIAamp DNA Mini kit (Qiagen, Hilden, Germany).
In all, 1mg of genomic DNA was treated with sodium bisulphite
using the EZ DNA MethylationTM kit (Zymo Research) according to
manufacturer’s procedure, respecting the recommended alterations
in protocol for consecutive Inﬁnium methylation analysis. Methyla-
tion status of 27578 distinct CpG sites was analysed using the
Inﬁnium HumanMethylation27 BeadChip array (Illumina, Inc., San
Diego) according to manufacturer’s protocol. Data acquisition was
done with the Illumina BeadArrayReader and quality control was
performed using the Methylation module (version 1.0.5) of the
GenomeStudioTM software (version 1.0.2.20706). Data normal-
isation was omitted due to resulting in essentially unchanged data
sets (background normalisation) or due to inapplicability (Loess,
quantile, Bayes) to methylation datasets because of their hetero-
scedasticity (Cancer Genome Atlas Research Network, 2011). For
quality control, a standard quality analysis was performed for each
array assessing Bisulphite conversion efﬁciency, hybridisation
efﬁciency and speciﬁcity, single base extension rate, target removal
as well as staining for negative and non-polymorphic probes
(GenomeStudio Controls Dashboard). Data handling, comparisons
and so on were performed with the Methylation module of the
GenomeStudio software package (Illumina), MS Excel, R 2.8.0-
2.11.1, Openstat and MicroarrayAnalyse v1.0 (Graessler, 2008).
CGI and promoter class annotation
Annotations for the Inﬁnium HumanMethylation27 provided by
Illumina were augmented with respect to (i) the position of the
analysed CpG relative to the nearest CGI (inside a CGI, in CGI shore
or 42kb away from an island) and (ii) the promoter class of the
gene afﬁliated to the evaluated CpG (high/intermediate/low CpG
content promoter). For all annotations, the human genome build
36.1 (hg18, March 2006) provided the basis.
For classiﬁcation of the CpG position relative to CGIs, the CGI
map provided by Bock et al (2007) (combined epigenetic score
40.5; genome assembly hg18/NCBI36) was used as reference; the
CpGs were classiﬁed into three categories according to Irizarry et al
(2009). Designation of the CpGs is as follows: ‘inside CGI’ if the CpG
was inside a CGI,‘CGI shore’ if the CpG was located within a 2-kb
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CGI 42kb).
Promoters of the gene loci afﬁliated to the analysed CpG sites
were classiﬁed according to their CpG content. First, we extracted
sequences ranging from positions  700 to þ500 relative to the TSS
from UCSC genome browser database, then calculated the CpG ratio
and the GC content of these sequences in sliding windows of 500
with 5bp offsets. For classiﬁcation criteria, we followed the
deﬁnition by Weber et al (2007). In short, promoters were deﬁned
as HCPs if at least one 500bp window contained a CpG ratio 40.75
together with a GC content 40.55 whereas in LCPs no 500bp
window reached a CpG ratio of at least 0.48. All promoters not
ﬁtting in either of the above promoter classes were termed ICPs.
Five differentially methylated gene promoters (and a total of 54
gene promoters on the Inﬁnium array) could not be classiﬁed due to
great distance to TSS or lack of annotation.
Hierarchical clustering
For unsupervised hierarchical clustering, the data sets were ﬁltered
for probes/CpG sites with a detection P-value of o0.05. CpGs not
ﬁtting into this criterion in at least one sample were excluded from
further analysis. The clustering was performed with the average
b-values (equals methylation percentage/100) of 24422 CpGs for
each sample using the cluster analysis function in GenomeStudio
applying Euclidean distance metrics.
For UPGMA (Unweighted Pair Group Method using Arithmetic
averages) clustering, the data sets for computation were assembled
as follows: a group-wise |Db|40.15 and Po0.01 (Mann–Whitney)
were set as ﬁltering criteria. In all, 276 probes ﬁtted into these
criteria. The methylation percentage of the CpG site corresponding
to each probe was extracted for each sample. Then, the methylation
values were categorised into 10 equal classes and imported into
MEGA4 (Tamura et al, 2007) in which the phylogenetic analysis was
conducted. The dendrogram was computed using the UPGMA
method applying the ‘number of differences’ model (Sneath and
Sokal, 1973). To determine the validity of the sample clustering
based on the methylation data, a bootstrap test (10000 sampling
steps) was used to calculate the percentage of replicate trees in
which the associated samples clustered together (Felsenstein,
1985). Bootstrap values of 0.7 or higher were considered signiﬁcant
and are shown next to the branches in Figure 1B.
Conventional BS and BPS
In all, 750ng genomic DNA was subjected to bisulphite conversion
using the Epitect
s Bisulﬁte Kit (Qiagen) or the EZ DNA Methylation
kit (Zymo Research) according to manufacturer’s protocol. Elution
of the converted DNA was generally performed with 26ml elution
buffer and 8ml of the eluted DNA were used as template in
subsequent PCRs. To ensure sufﬁcient amount of product,
ampliﬁcations were generally performed as nested PCRs.
PCR and sequencing primers for BPS were deduced using the
PyroMark
s Assay Design 2.0 software (Qiagen). Primers for pre-
ampliﬁcation and conventional BS were designed manually or with
the help of BiSearch primer design tool (http://bisearch.enzim.hu)
and evaluated using the GeneRunner software (v3.05 Hastings
Software, Inc.). Primers were obtained from Eurogentec S.A. or
Sigma-Aldrich Corp. Biotinylated primers were ordered HPLC
puriﬁed, all other primers desalted. PCR and sequencing primers
are listed in Supplementary Table S7.
The pre-ampliﬁcation PCR was conducted with primers (see EF,
ER primers in Supplementary Table S7) amplifying 400–720bp
spanning the CpG of interest and additionally as many as possible
neighbouring CpG sites. CpG sites in the annealing positions of the
PCR primers were avoided where possible; otherwise primers were
ordered with ambiguities at the respective positions. PCR was
conducted with 3mM MgCl2, 1mM of each dNTP, 12% (v/v)
DMSO, 500nM of each primer and optionally 500mM Betaine in
heated-lid thermocyclers under the following conditions: 951C 3:00;
25  (941C 0:30; 511C 0:40; 721C 1:30); 721C 5:00 and cooled
afterwards to 101C.
For conventional BS, nested PCRs were conducted as described
above using 35 PCR cycles and a decreased elongation time of 1min
(for PCR primers cf. Supplementary Table S7). PCR products were
separated on a 1% agarose gel and single bands were cut and eluted
from the gel. Cloning of the nested PCR products was performed
with TOPO TA Cloning
s kit (Invitrogen Corp.) and the plasmids
were sequenced by Genoscreen.
For pyrosequencing, a nested PCR was performed with primers
designed by the PyroMark Assay Design software (Qiagen) using
the HotStarTaq PCR kit (Qiagen) according to manufacturer’s
recommendations. Reactions were performed in heated-lid thermo-
cyclers under the following conditions: 951C 15:00; 45  (941C
0:30; 551C 0:30; 721C 0:30); 721C 10:00 and ﬁnally cooled to 81C.
Sample preparation and pyrosequencing reactions were performed
with the Pyromark Q24 system (Qiagen). For validation of Inﬁnium
assay-derived DNA methylation by BPS, usually three to ﬁve
randomly chosen samples from each group (CTL and T2D) were
analysed and DNA methylation degrees were averaged.
Microarray gene expression studies
In all, 100ng total RNA was prepared and hybridised onto
Affymetrix Human HG-U133A chips, according to the protocols
described in the Affymetrix GeneChip
s Expression Analysis
Manual (Affymetrix, Santa Clara, CA). Chips were scanned in an
Affymetrix GeneChip Scanner 3000 and their quality veriﬁed with
the Microarray Analysis Suite 5.0 (Affymetrix) software and
functions from the R/Bioconductor affy and affyPLM packages
(Gautier et al, 2004; Bolstad et al, 2005) (R version 2.8.0;
Bioconductor version 2.3). Raw gene expression data were normal-
ised using the Robust Multiarray Average (RMA) method described
by Irizarry et al (2003) implemented in the affy package. Gene
expression ratios were calculated using the limma package by
ﬁtting a linear model on each gene (Smyth, 2005).
For comparison of differentially methylated loci with expression
proﬁles of non-diabetic islets (Bhandare et al, 2010), we utilised the
extracted expression data (downloaded from ArrayExpress;
accession number E-MTAB-191; http://www.ebi.ac.uk/microarray-
as/ae/).
INS-1E cell and human islet culture
The rat insulin-producing INS-1E cell line (a kind gift from Professor
C Wollheim, Centre Medical Universitaire, Geneva, Switzerland)
was cultured in RPMI-1640 (with 2mM GlutaMAX-I) containing 5%
FBS (Asfari et al, 1992; Cnop et al, 2007a) and used at passages
59–73. Human islets were isolated from 11 organ donors (age 69±6
years; body mass index 26±1kg/m
2) in Pisa, Italy, as described
above. The islets were cultured in Ham’s F-10 medium containing
6.1 or 28mM glucose as previously described (Cunha et al, 2008;
Igoillo-Esteve et al, 2010; Ladriere et al, 2010). The percentage of
b-cells, assessed in dispersed islet preparations following staining
with mouse monoclonal anti-insulin antibody (1:1000, Sigma) and
donkey anti-mouse IgG Rhodamine (1:200, Jackson Immuno
Research Europe, Soham, Cambridgeshire, UK), was 53±3%.
Palmitate and oleate (Sigma-Aldrich, Schnelldorf, Germany) were
dissolved in 90% ethanol, and used at a ﬁnal concentration of
0.5mM in the presence of 1% BSA (Cunha et al, 2008). The
chemical ER stressors THA (diluted in DMSO and used at a ﬁnal
concentration of 1mM), CPA (diluted in DMSO and used at ﬁnal
concentration of 25mM), TUN (diluted in PBS and used at a ﬁnal
concentration of 5mg/ml) and BRE (diluted in ethanol and used at a
ﬁnal concentration of 0.1mg/ml) were obtained from Sigma-
Aldrich. The control condition contained similar dilutions of
vehicle.
Assessment of b-cell death
Cell death was measured using the neutral red kit (Sigma, TOX4)
following manufacturer’s instructions. Brieﬂy, cells were incubated
with 17mM neutral red for 3h at 371C, washed and the dye
extracted for absorbance measurement in a spectrophotometer.
Quantitative evaluation of INS-1E cell apoptosis was done by
ﬂuorescence microscopy following staining with the DNA-binding
dyes propidium iodide (5mg/ml) and Hoechst 33342 (5mg/ml)
(Cnop et al, 2007a). Caspase 3 activation was assessed by western
blot, as previously described (Gurzov et al, 2009), using anti-
cleaved caspase 3 antibody (1:1000; from Cell Signaling, Beverly,
MA, USA).
RNA interference
Genes were knocked down using siRNA. The Niban siRNA was
SMARTpool (L-080179-01 from Dharmacon, Chicago, IL, USA).
Stealth RNAi (Invitrogen, Carlsbad, CA) was used for CHAC1
(RSS324745), MKNK2 (RSS312292), PER2 (RSS329646), BCL2
(RSS340652) and NR4A1 (RSS330510). The siRNAs for SFRS2IP
(s161636) and GUCA2B (s133784) were Silencer Select from
DNA methylation proﬁling of type 2 diabetic islets
M Volkmar et al
&2012 European Molecular Biology Organization The EMBO Journal VOL 31 | NO 6 | 2012 1421Ambion (Austin, TX). A negative control (siCTL) of 21 nucleotide
duplex RNAwith no known sequence homology was obtained from
Qiagen. Lipid–RNA complexes were formed in Optimem1 with
1.5ml Lipofectamine 2000 (Invitrogen) to 150nM siRNA and added
at a ﬁnal concentration of 30nM siRNA for transfection as described
(Cunha et al, 2008). Transfected cells were cultured for 2 days and
subsequently treated. The achieved knockdown was 74.8±10.4%
for MKNK2 (P¼0.03), 86.4±3.5% for GUCA2B (P¼0.003),
34.2±12.9% for PER2 (P¼0.098), 58.3±5.9% for SFRS2IP
(P¼0.04), 72.4±3.2% for CHAC1 (P¼0.02), 72.5±3.6% for
NR4A1 (P¼0.001), 47.2±3.8% for Bcl-2 (P¼0.01) and
50.7±4.8% for NIBAN (P¼0.02), as measured at the mRNA level,
except for Bcl-2 that was measured by western blotting.
Real-time PCR
Poly(A)þ RNA was isolated and reverse transcribed as previously
described (Chen et al, 2001). The PCR was done in 3mM MgCl2,
0.5mM forward and reverse primers, 2mlS Y B RG r e e nP C Rm a s t e rm i x
(Qiagen) and 2ml cDNA. Standards for each gene were prepared using
appropriate primers in a conventional PCR. The samples were
assayed on a LightCycler instrument (Roche Diagnostics, Mannheim,
Germany) and their concentration was calculated as copies per ml
using the standard curve (Overbergh et al, 1999). The expression level
of the gene of interest was corrected for the expression of the
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
(Gapdh, for INS-1E cells) or b-actin (for human islets). PCR primers
are listed in Supplementary Table SXXX. The different treatments
utilised in the study did not change expression of the housekeeping
gene (Igoillo-Esteve et al, 2010; data not shown).
Statistics
Signiﬁcance of group-wise differences in DNA methylation proﬁles
was measured by Mann–Whitney rank-sum test, Po0.01 was
considered signiﬁcant. Taking into account inter-individual differ-
ences in methylation levels and following Illumina Inc. recommen-
dations, a 15% group-wise difference of methylation levels was set
as a cutoff additional to PMann–Whitneyo0.01. Correlation between
methylation values by Inﬁnium and BPS was computed using
Pearson’s correlation test. Differences between distributions (CpG
localisation, promoter class) were calculated with w
2 goodness-of-ﬁt
test (R 2.11.1); P-values were estimated from the resulting w
2 value.
Signiﬁcance of gene expression differences was tested by Bayes
moderated t-test and P-values were FDR adjusted using Benjamini-
Hochberg method (R package limma; Smyth, 2005); adj. Po0.05
was considered signiﬁcant. Differences in glucose-stimulated
insulin secretion, methylation as analysed by BPS and gene
expression as analysed by RT–qPCR were assessed by Student’s
t-test, Po0.05 was considered signiﬁcant. Data are represented as
mean±s.d. unless indicated otherwise.
Accession codes
DNA methylation data sets for pancreatic islets and whole blood
have been submitted to the NCBI Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo) under accession numbers
GSE21232 and GSE34008, respectively.
Supplementary data
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